ClinicalTrials.gg
RecruitingNCT06229925Updated Mar 27, 2024

Effects of Transcranial Direct Current Stimulation Versus Sham in Subacromial Pain Syndrome

An interventional study of Experimental Stimulation and Sham Stimulation in Subacromial Pain Syndrome and Transcranial Direct Current Stimulation, sponsored by Universidade Federal do Rio Grande do Norte. Recruiting at 1 site in Brazil. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Universidade Federal do Rio Grande do Norte · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Chronic Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Chronic Pain · Brazil.

Planned enrollment
46th of 61
32 · median 60
Started
2024
with 2 others
No phase
48 of 67
8 open now
Primary completion
2024-10
later than 2 of 11 live
Registered
54th of 67
by date
Lead sponsor
4 of 67
Universidade Federal do Rio Grande do Norte

Among the 67 studies in Chronic Pain with a site in Brazil, this one is the 46th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2024, is one of 48 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 54th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

10 of the 67 studies in Chronic Pain with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Chronic Pain with a site in Brazil, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effects of applying Transcranial direct current stimulation on pain levels and function, quality of life, muscle strength and range of motion in individuals with subacromial pain syndrome.

Read the detailed description

This is a controlled, randomized and blind clinical trial, which will be carried out with individuals from the city of Natal/RN, aged between 18 and 65 years, of both sexes, diagnosed with subacromial pain syndrome, who present a level of pain greater than 3 on the Numerical Pain Scale, at rest, for at least 3 months. The research sample will be non-probabilistic, in which they will be randomly distributed into two distinct groups: active tDCS (active stimulation) and sham tDCS (stimulation turned off after 20 seconds). This research was submitted to the UFRN Research Ethics Committee through the national interface Plataforma Brasil. This research covers the ethical aspects guided by Resolution 466/2012 of the National Health Council and the Declaration of Helsinki for research with human beings. In addition, the research will be registered in Clinical Trials. All data will be recorded in the laboratory's database under confidentiality and may only be processed by the responsible researchers. The study will only begin after the issuance of the reference opinion approving the project. All subjects will be duly informed and guided regarding the scheduled procedures, which will only be carried out after reading, accepting and signing the Informed Consent Form. After approval by the Research Ethics Committee, following resolution 466/2012, a pilot study was carried out to adapt all research procedures, as well as training the researchers involved. Volunteers will be duly informed about the objectives and advantages of their participation in the study, and will then undergo an assessment of pain sensation, using the Numerical Pain Scale; assessment of shoulder range of motion, using the Smartphone clinometer application; assessment of muscle strength through flexion, hyperextension, medial and lateral rotation movements of the shoulder, using a portable dynamometer; will complete the Douleur Neuropathique 4 questionnaire (DN4) to screen for neuropathic pain, the Disabilities of the arm, shoulder and hand questionnaire (DASH) to assess upper limb function, and the Short Form 36 Health Survey questionnaire (SF-36) to assess health-related quality of life. They will then undergo 20 minutes of stimulation for 5 consecutive days, according to the pre-determined group. The assessments will be repeated at the end of the intervention and in a 1-week follow-up, in which they will receive an educational booklet.

03

Conditions studied

  • Subacromial Pain Syndrome
  • Transcranial Direct Current Stimulation

Browse trials for

Keywords

  • Transcranial Direct Current Stimulation
  • Neuromodulation
  • Pain in the shoulder
  • Chronic pain
  • Treatment
04

Who can participate

Ages eligible
20 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral pain in one shoulder
  • Pain level ≥ 3 on the Numerical Pain Scale (END), at rest, for at least 3 months
  • No previous treatment with tDCS
  • Present graded disability on the DASH questionnaire (> 15 points)
  • At least three positive tests, among the five indicated below: Neer, Hawkins, Jobe, Patte or painful abduction arch.

Exclusion criteria

Exclusion Criteria:

  • Indication for surgical repair and/or history of shoulder surgery
  • Shoulder fracture and/or dislocation
  • Partial or total rupture of one of the rotator cuff tendons and/or the long head of the biceps
  • Fibromyalgia
  • History of epilepsy
  • Panic syndrome
  • Implantable devices in the skull
  • Significant neurological or psychiatric diseases
  • Severe cardiopulmonary, renal and hepatic diseases
  • Current pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental Stimulation

    Active direct current stimulation for 20 minutes.

    Device: Experimental Stimulation

  • Sham comparator
    Sham Stimulation

    Sham direct current stimulation for 20 minutes.

    Device: Sham Stimulation

Interventions

  • DeviceExperimental Stimulation

    Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.

  • DeviceSham Stimulation

    Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.

06

What researchers measure

Primary outcomes

  1. Pain intensity (numerical pain rating scale)

    Pain intensity measured by numerical pain rating scale, measured on an 11-point where 0=no pain and 10=worst possible pain.

    Time frame: Up to 1 week of follow-up

Secondary outcomes

  1. Peak of muscular torque

    Evaluate the peak of muscular torque using the hand-held dynamometer.

    Time frame: Up to 1 week of follow-up

  2. Range of motion (ROM)

    Evaluate the range of motion using the Smartphone clinometer application

    Time frame: Up to 1 week of follow-up

  3. Degree of disability of the upper limbs

    Evaluate the degree of disability of the upper limbs using the Disabilities of the arm, shoulder and hand (DASH) questionnaire. Total scores range from 0 to 100 for each dimension, with higher values indicating worse upper limb function.

    Time frame: Up to 1 week of follow-up

  4. Health-related Quality of Life

    Evaluate the health-related Quality of Life using the Quality of Life questionnaire (SF-36). The score for this questionnaire ranges from 0 to 100, with higher values indicating a better general state of health.

    Time frame: Up to 1 week of follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2024, 6 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Jan 29, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Oct 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06229925
Lead sponsor
Universidade Federal do Rio Grande do Norte
Responsible party
Jamilson Simões Brasileiro (Professor and Researcher, Universidade Federal do Rio Grande do Norte) — Principal investigator
First posted
Jan 29, 2024
Start date
Mar 4, 2024
Primary completion
Oct 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Mar 27, 2024

Study contacts

Jamilson S Brasileiro, PhD
Contact
brasileiro@ufrnet.br
+55 84 3342-2008
Vinícius Dantas, Esp
Contact
viniciuus.dantas@gmail.com
+55 84 99828-1674
Vinícius Dantas, Esp
principal investigator · Universidade Federal do Rio Grande do Norte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion